CMI adopts orphan drug field with dedicated center of excellence

In a feature by Fierce Pharma, CMI Media Group announced the launch of its Rare Disease Center of Excellence (CoE), a specialized framework designed to address the unique marketing challenges of orphan drugs and rare therapies. Building on CMI’s proven track record of supporting 67 rare disease brand launches, the new CoE combines micro-precision data targeting with deep advocacy and referral network mapping. As CEO Susan Dorfman highlighted, the center delivers the tailored expertise of a boutique agency paired with the scale and advanced analytics of a global media network, helping pharma partners shorten the diagnosis journey and accelerate access to life-changing treatments for patients.

Read the full article from Fierce Pharma here.